Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.78 |
| ▸ | PRSS1 | P07477 | 17/20 | 0.78 |
| ▸ | F2 | P00734 | 14/20 | 0.78 |
| ▸ | F9 | P00740 | 2/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982997 | 0.88 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7367326 | 0.87 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7365282 | 0.84 | F10 (0.81) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL6613306 | 0.83 | F2 (0.56) | F10PRSS1F2F9 | |
| SCHEMBL7438126 | 0.77 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7449310 | 0.75 | F10 (1.00) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7366733 | 0.75 | F10 (0.75) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL7967893 | 0.73 | F10 (0.49) | F10PRSS1F2F9PRSS2 | |
| SCHEMBL5094309 | 0.71 | F10 (0.56) | F10PRSS1F2F9 | |
| Hydrochloric Acid SCHEMBL5099759 | 0.70 | F10 (0.55) | F10PRSS1F2F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015429-B1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6552042-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | HAN QI (US) | 2001-09-13 | — | — | US | disclosed |
| US-6207697-B1 | AMIDINYL-SUBSTITUTED RINGS; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; STROKES; SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-1015429-A1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | Du Pont Pharmaceuticals Company (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012903-A1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | F12, F13B, F11 | F10 10/4885PRSS1 245/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.